Hosted on MSN

Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum

Daniel O'Day, Chairman & CEO, stated that "our third quarter earnings underscore the growing momentum you're seeing from Gilead today, which is driven by our strong portfolio and the impressive ...
Business Wire

Victory! AHF, 100 Organizations Kill Gilead’s Greedy Drug Price Hikes

Groups welcome reversal of Gilead’s price gouging decision that would have resulted in fewer people with HIV getting access to lifesaving treatment. AHF sent a letter signed by over 100 organizations ...